Fujirebio launches Lumipulse G GFAP assay, a 35-minute GFAP test for neurological research.

Fujirebio has launched the Lumipulse G GFAP assay, a fully automated, random-access test for Research Use Only (RUO), available in the US, Japan, Europe, and other regions by September. The Chemiluminescent Enzyme Immunoassay (CLEIA) measures glial fibrillary acidic protein (GFAP) in human plasma and serum in 35 minutes, adding to their neuro assay portfolio. Fujirebio plans to continue their engagement in biomarker-based testing for neurological diseases.

July 26, 2024
3 Articles

Further Reading